Notably, increased CSF CHI3L1 levels have been observed in patients progressing to clinically definite MS, correlating with the number of gadolinium-enhanced lesions, disability progression, and a faster transition to confirmed MS [161]. This evidence concerns the gene CHI3L1 and myeloid sarcoma.